Argentina

The primary regulatory authority for health products in Argentina is the Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT), operating under the Ministry of Health (Ministerio de Salud de la Nación). ANMAT was established by Decree 1490/1992 and is responsible for the authorization, registration, surveillance, and control of pharmaceuticals, medical devices, diagnostics, food, and digital health products. The general approval process requires manufacturers or local representatives to submit a registration dossier to ANMAT, which then conducts a technical and administrative review before issuing a marketing authorization known as the Certificado de Autorización or Certificado de Registro. Risk classification for medical devices follows MERCOSUR Resolution GMC 40/00 framework, while pharmaceuticals are governed by national pharmacopoeia standards and aligned, in part, with ICH guidelines.

A mandatory local legal representative (apoderado local) or authorized importer must be established in Argentina to submit and maintain product registrations. ANMAT accepts dossiers largely aligned with the Common Technical Document (CTD) format for pharmaceuticals, and specific technical requirements for medical devices and diagnostics are outlined in individual ANMAT dispositions. Argentina is a member of MERCOSUR, and the bloc's harmonized technical regulations significantly influence submission standards. Notable recent reforms include the expansion of ANMAT's digital submission portal (SIGA and related platforms), expedited pathways for innovative and orphan medicines introduced under Disposición 1773/2018 and subsequent updates, and growing regulatory attention to software as a medical device (SaMD) and digital health solutions. ANMAT also participates in international reliance initiatives, occasionally accepting prior approvals from recognized regulatory authorities such as the FDA, EMA, or Health Canada to streamline review timelines for certain product categories.

Public procurement in Argentina operates through a multi-tiered structure. At the national level, the Ministerio de Salud de la Nación coordinates centralized purchasing programs for essential medicines, vaccines, and medical supplies, often channeled through the Programa Nacional de Garantía de Calidad de la Atención Médica and the Programa SUMAR. The national government also oversees procurement through PAMI (Instituto Nacional de Servicios Sociales para Jubilados y Pensionados), which is one of the largest purchasers of pharmaceuticals in the country due to its coverage of the retired population. Federal procurement tenders are published on the Argentina Compra platform (formerly COMPR.AR), managed by the Oficina Nacional de Contrataciones (ONC). Given Argentina's federal structure, each of the 23 provinces and the Autonomous City of Buenos Aires retains significant authority over its own health procurement, leading to considerable fragmentation. Provincial health ministries and hospital networks conduct their own tender processes, which can vary substantially in requirements, pricing, and timelines, making market access strategies complex and regionally differentiated.

The private sector represents a substantial share of health product consumption in Argentina and is served through a network of pharmaceutical distributors, pharmacy chains, and private hospital groups, with prepaid health plans (medicina prepaga) and obras sociales (employer-based social health insurance funds) playing a central role in reimbursement decisions. Reimbursement by obras sociales is often governed by the Programa Médico Obligatorio (PMO), which defines the mandatory benefit package. Donor-funded procurement channels, including UNICEF, PAHO, and the Pan American Health Organization's revolving fund for vaccines, are active in Argentina primarily for immunization programs and select public health initiatives, though Argentina's upper-middle-income status limits broad eligibility for Global Fund or Gavi mechanisms. Local manufacturing is strongly encouraged through national industrial policy: products manufactured domestically may benefit from preferential treatment in public tenders, and the government has historically supported national pharmaceutical production capacity through initiatives aligned with the Ley de Promoción Industrial. Companies are advised to assess local manufacturing partnerships or technology transfer arrangements as part of long-term market access strategies.